Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy
NegativeFinancial Markets

Leerink Partners has downgraded Innate Pharma's stock due to a strategic shift towards antibody-drug conjugates (ADCs). This decision reflects concerns about the company's future performance and market position, which could impact investor confidence and stock value. Understanding these shifts is crucial for stakeholders as they navigate the evolving landscape of biopharmaceuticals.
— Curated by the World Pulse Now AI Editorial System